课题基金 / 基金详情

Wiskott-Aldrich syndrome protein (WASp) signaling in the oncogenesis of T celllymphomas

Wiskott-Aldrich syndrome protein (WASp) signaling in the oncogenesis of T celllymphomas
T 细胞淋巴瘤发生过程中的 Wiskott-Aldrich 综合征蛋白 (WASp) 信号传导
批准号:
10071043
负责人:
Carlos A. Murga-Zamalloa
金额:
$8.25万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-01-01 至 2021-08-31

项目摘要

项目成果

Carlos A. Murga-Zamalloa的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract T-cell lymphomas display shorter relapse intervals and poor overall survival. Targeted therapies for T-cell lymphomas are lacking, and there is no established standard of care for patients at relapse. The limited information on the specific molecular signals that are activated in T-cell lymphomas hampers the development of effective therapies. Emergent research has demonstrated that aberrant activation of proteins involved in actin organization is critical for cancer metastasis and tumor growth. The candidate preliminary studies demonstrate that a large network of actin organizing proteins is activated during the development of T-cell lymphoma. Also, the major actin regulatory protein Wiskott-Aldrich syndrome protein (WASp) increases the dissemination and growth of a subtype of T-cell lymphoma, anaplastic large cell lymphoma (ALCL). These preliminary findings are very exciting, as identified a major actin regulatory protein as key determinant for lymphoma development. However, whether WASp also plays a role in lymphoma development in more common and aggressive types of T-cell lymphomas needs to be determined. The candidate novel preliminary findings demonstrate that WASp is expressed and activated in the most common type of T-cell lymphoma in the United States, peripheral T- cell lymphoma, non-otherwise specified (PTCL-NOS). In addition, WASp expression decreases the sensitivity of primary T-cell lymphoma cells to available chemotherapeutics, suggesting a role of WASp in chemotherapy resistance. Moreover, WASp can activate downstream proteins known to increase tumor proliferation and dissemination. Among these proteins, activation of lymphocyte specific protein 1 (LSP1) and extracellular signal-regulated kinase (ERK) in T-cell lymphomas has been validated. Importantly, ERK pathway can be inhibited with drugs that are currently in clinical trials for other types of cancer. The central hypothesis is that WASp and its downstream signals (ERK and LSP1) are therapeutic targets for patients with a diagnosis of T-cell lymphoma. In this proposal, I will evaluate 1) the role of WASp and its downstream signals (ERK and LSP1) during lymphoma growth, 2) the role of WASp dependent actin re-organization during T-cell lymphoma dissemination, 3) the signaling pathways that mediate WASp-dependent chemotherapy resistance, and 4) the oncogenic role of WASp in-vivo using a mice model of T-cell lymphoma with knock-down expression of WASp. The candidate long term career goal is to develop as a successful independent physician-scientist with a research focus in the pathobiology of T-cell lymphomas. The candidate career development plan is structured in three main components to help achieve its goals; 1) Gain technical and clinical skills for translational studies on T-cell lymphomas, 2) Expand its knowledge related to tumor progression and 3) Develop skills to become an independent scientist and write an R01 application to the NCI.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas.
刺激性淋巴瘤中的双重激酶 - 溴结构域抑制剂伏拉替氏菌的polo样酶1(PLK-1)和C-MYC抑制作用。
DOI: 10.18632/oncotarget.22967
发表时间: 2017-12-29
期刊: Oncotarget
影响因子: --
作者: [Murga-Zamalloa C, Polk A, Hanel W, Chowdhury P, Brown N, Hristov AC, Bailey NG, Wang T, Phillips T, Devata S, Poonnen P, Gomez-Gelvez J, Inamdar KV, Wilcox RA]
通讯作者: Wilcox RA
DOI: 10.1186/s13000-022-01237-0
发表时间: 2022-06-25
期刊: Diagnostic pathology
影响因子: 2.6
作者: []
通讯作者:
Wiskott-Aldrich syndrome protein (WASp) signaling in the oncogenesis of T cell lymphomas
国内基金
海外基金
活性优化型先导编辑器精准替换WAS基因 突变热点区域治疗Wiskott-Aldrich综合 症小鼠模型研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    支胜尧
  • 依托单位:
Wiskott-Aldrich综合征中的免疫缺陷:WASH蛋白在B细胞中的功能
  • 批准号:
    32311530061
  • 项目类别:
    国际(地区)合作与交流项目
  • 资助金额:
    10万元
  • 批准年份:
    2023
  • 负责人:
    刘超红
  • 依托单位: